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a  b  s  t  r  a  c  t
Objective: The aim of this study was to evaluate the effect of licorice in H. pylori eradication
in  patients suffering from dyspepsia either with peptic ulcer disease (PUD) or non-ulcer
dyspepsia (NUD) in comparison to the clarithromycin-based standard triple regimen.
Methods: In this randomized controlled clinical trial, 120 patients who had positive rapid
urease test were included and assigned to two treatment groups: control group that received
a  clarithromycin-based triple regimen, and study group that received licorice in addition
to  the clarithromycin-based regimen for two weeks. H. pylori eradication was assessed six
weeks after therapy. Data was analyzed by chi-square and t-test with SPSS 16 software.
Results: Mean ages and SD were 38.8 ± 10.9 and 40.1 ± 10.4 for the study and control groups,
respectively, statistically similar. Peptic ulcer was found in 30% of both groups. Response to
treatment was 83.3% and 62.5% in the study and control groups, respectively. This difference
was statistically signiﬁcant.
Conclusion: Addition of licorice to the triple clarithromycin-based regimen increases H. pylorieradication, especially in the presence of peptic ulcer disease.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
lymphoma).Introduction
Helicobacter pylori (H. pylori) is a Gram negative S shaped ﬂag-
ellated bacteria infecting half of mankind with a very variable
prevalence depending on different factors such as race, age,
and socioeconomic status ranging from a low prevalence in
developed countries to a prevalence as high as 80% in devel-
oping countries like Iran.1 H. pylori is a successful pathogen
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which can persistently survive in the stomach of infected
persons throughout his/her life and if it results in chronic
inﬂammation serious digestive diseases may ensue such as
chronic gastritis, peptic ulcer disease (PUD), gastric cancer,
and gastric MALT-oma (mucosa associated lymphoid tissue
2Peptic ulcer disease is one of the consequences of H. pylori
infection and is one of the most common treatable diseases
worldwide. The commonest cause of peptic ulcer is H. pylori
lsevier Editora Ltda. This is an open access article under the CC
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nd if not eradicated it will result in 50–80% relapse in 6–12
onths after treatment interruption,3 but if successfully
reated its recurrence will drop to 6–20%, as reported by two
eparate meta-analyses.4,5
Relation between dyspepsia and H. pylori is unclear, but
radication leads to symptoms improvement in 7.1% of
atients.6
American College of Gastroenterology (ACG) recommends
he treatment of H. pylori in all infected patients irrespective
f the presence of ulcer. Recommended ﬁrst line standard
egimen by ACG for the treating H. pylori is a triple regimen
ontaining clarithromycin, amoxicillin or metronidazole, and
roton pump inhibitor (PPI) for 10–14 days. Quadruple regimen
s recommended in areas where the prevalence and resistance
o clarithromycin or metronidazole is more  than 20%, or if the
rst choice has been tried recently or repeatedly.7
Antibiotic resistance to H. pylori has increased in recent
ast years. Compared to 2010 the resistance rate to clar-
thromycin and amoxicillin in 2012 has raised signiﬁcantly.8
he effectiveness of the present therapeutic regimen is still
ot satisfactory and despite several studies the best treatment
egimen for treating H. pylori remains a challenging clinical
ilemma.9 Antibiotic resistance and adverse effects in addi-
ion to poor patient compliance have limited the efﬁcacy of
. pylori treatment. Therefore, the role of herbal medicine has
een evaluated in the treatment of H. pylori, including licorice
liquorice).10
Licorice herb (Glycyrrhiza glabra - G. glabra)  has routinely
een used for centuries in traditional Chinese.11 Roots and
hizomes of this herb has been reported to be antioxidant,
ntimicrobial, and antiviral.12,13 Furthermore, G. glabra has
nti-inﬂammatory, anticancer, and anti-ulcer activity.14–16
icorice is extracted from the root of G. glabra herb and one
f its active ingredient is glycyrrhizin acid, which due to its
fﬁnity to mineralocorticoid receptors may result in edema
nd hypertension. Therefore, it should be used with cau-
ion in patients suffering from cardiovascular disease and/or
ypertension.17 (Fig. 1).
Fig. 1 – Photograph of Glycyrrhiza glabra herb.6;2 0(6):534–538 535
There two types of action of licorice in PUD and against H.
pylori: (1) a repairing effect in PUD: protective mucosal effect by
secreting a material named as secretin18; and (2) antibacterial
and anti-adhesive effect against H. pylori by inhibiting DNA
gyrase (a crucial enzyme for bacterial replication and tran-
scription) and dihydrofolate reductase enzyme blockage.19
In addition, the polysaccharide released from the root of
licorice plays an inhibiting role in H. pylori adhesion to gas-
tric mucosa.20 Besides, treatment with licorice for patients
suffering from dyspepsia improves their clinical complaints.21
Owing to the rise of H. pylori resistance against antibiotics
and the effectiveness of licorice for treating H. pylori, this study
was designed to compare the efﬁcacy of adding licorice to
the standard clarithromycin-based triple regimen in the treat-
ment of H. pylori.
Material  and  methods
This randomized controlled clinical trial was conducted in
Velayat teaching hospital in Qazvin (northwest of Iran). A total
of 120 patients over 16 years of age referred for esophagogas-
troduodenoscopy (EGD) at the digestive disease outpatient
department due to gastrointestinal complains entered this
study from May to December of 2015. Biopsy was performed
when indicated by the endoscopist.
Patients with a positive rapid urease test were included in
this study if none of the following conditions were present:
pregnancy, use of proton pump inhibitor (PPI), bismuth or
antibiotic in the past two weeks, gastrointestinal (GI) bleed-
ing or any complication of PUD, giant ulcer, gastric ulcer,
ethanol consumption or substance abuse, chronic underlying
disease like diabetes mellitus, hypertension, cirrhosis, cere-
brovascular attack, coronary artery disease, and gastric cancer.
Patients who were reluctant to continue the treatment or com-
plete the follow-up or suffering from a comorbidity needing
non-steroidal anti-inﬂammatory drugs (NSAIDs) or antibiotic
to be continued during the period of study were excluded.
Informed consent was obtained from all eligible. Sixty patients
were randomly assigned to receive one of two treatment regi-
mens: triple regimen consisting of clarithromycin (500 mg
BID) + Amoxicillin (1 gr qd) + 20 mg  BID of Omeprazole (control
group) or the same regimen supplemented by licorice [D-Reglis
(380 mg  BID) made by Iran daruc Pharmacy Company] for two
weeks (LR group). Both groups received at least four weeks
of treatment with omeprazole 20 mg  daily subsequently. Two
weeks after completing the treatment, H. pylori eradication
was assessed with H. pylori stool antigen (HPSA) test by Ag
ACON Biotech (Hang Zhou) Co., Ltd.
This study is registered at Iran Registration Clinical Trial
Center and was approved with the Irct registration number:
IRCT2014061718124N1.
The outcome of this study was H. pylori eradication. Data
were stored at SPSS 16 software and analyzed by using of t-test,
chi-square test. A p-value <0.05 was considered signiﬁcant.Results
Out of 120 eligible patients, 110 patients completed the study
complying with the prescribed medications and follow-up;
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2 patients was lost follow up
56 patients came back for follow up
2 patients discontinued treatment
for side effects
56 patients completed treatment
course
Analysis
54 patients completed treatment
course
2 patients discontinued treatment
for side effects
4 patients was lost follow up




oxicFig. 2 – Study ﬂow chart (Control Group: Clarithromycin +Am
Licorice + Clarithromycin +Amoxicillin + Omeprazole).
54 patients were assigned to the licorice group (LR) and 54
patients to the control group (schematic presentation of study
groups is illustrated in Fig. 2).
Demographic variables of both treatment groups were sim-
ilar. Mean ages were 38.8 and 40.1 years for the LR and
control groups, respectively (p = 0.56); 35 patients (51.0%) of
LR group and 33 persons (48.1%) of the control group were
female (p > 0.05). Patients in two groups were also similar
regarding to their clinical characteristics (initial complaints
and endoscopic ﬁndings). Frequency distribution of their clin-
ical characteristics is shown in Table 1.











Abdominal pain 37 (61.7%) 42(70%) 0.442
Early satisﬁed 8(13.3%) 5(8.3%) 0.558
Bloating 12(20.0%) 15(25%) 0.662
Heart burn 13(21.7%) 15(25%) 0.829
Nausea 2(3.3%) 4(6.7%) 0.679
Endoscopic ﬁnding
Duodenal ulcer 21(35.0%) 18(30.0%) 0.697
Antral erythema 29(48.3%) 32(55.3%) 0.715






7(11.7%) 8(13.3%) 1.000illin + Omeprazole regimen, Licorice (LR) Group:
Furthermore, both groups had similar rates of endoscopic
diagnosis of PUD or non-ulcer dyspepsia (NUD): 21 (35%) and
18 patients (30%) in the LR and control groups, respectively,
had PUD (Table 2).
HPSA negative, the surrogate for H. pylori eradication and
positive therapeutic response, was 83.3% in the LR group com-
pared to 62.5% in the control group (p = 0.018). Response rate
based on endoscopic ﬁndings was signiﬁcantly higher for the
LR group to treat PUD, but not for NUD (Table 3).
Discussion
This study was conducted with the aim of evaluating the
effectiveness of licorice in H. pylori eradication of patients suf-
fering from dyspepsia (both PUD and NUD) compared to the
clarithromycin-based standard triple regimen. Results of this
study showed that adding a low dose licorice (D-Reglis 380 mg
BID) to the standard triple treatment results in a more  effective
H. pylori eradication, especially in patients with PUD.  During
the recent past decades many  studies on H. pylori infection
have been conducted to deﬁne the adequate therapy. As H.
pylori is considered a major risk factor for upper digestive
problems guidelines often recommend treating all infected
persons irrespective of the clinical presentation. Besides the
clinical impact, H. pylori eradication would also prevent its
spread.22In the present study the addition of licorice increased the
effectiveness of H. pylori eradication compared to standard
clarithromycin-based triple regimen, a ﬁnding similar to pre-
vious in vitro studies.20,23
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Table 2 – Endoscopic diagnosis of licorice (LR) and control groups.
Endoscopic diagnosis Peptic ulcer Non-ulcer dyspepsia Total p-Value
LR group (N:60) 21 (35.0%) 39 (65.0%) 60 (100.0%) 0.697
Control group (N:60) 18 (30%) 42 (70.0%) 60 (100.0%)
Total 39 (32.5%) 81 (67.5%) 120 (100.0%)




LR  group (N:54) Total Control group (N:56) Total p-Value
Negative N (%) Positive
N (%)





Non-ulcer dyspepsia 28 (82.4%) 6 (17.6%) 34 (100%) 27 (67.5%) 13 (32.5%) 40 (100%) 0.186
Peptic ulcer disease 17 (85.0%) 3 (15.0%) 20 (100%) 8 (50%) 8 (50%) 16 (100%) 0.034b




































iii) Final approval of the version to be published; Ali Akbara Helicobacter pylori stool antigen.
b Signiﬁcant level was >0.05.
Toshio Fukai investigated the anti-H. pylori in vitro effect of
arious preparations of licorice and showed that the leaves
nd rhizomes of this herb prevented the multiplication of H.
ylori. In addition, he also proved that licorice had anti-H. pylori
ffect against the species resistant to clarithromycin.24
Asha MK  reported that G. glabra has antimicrobial effect
gainst several Gram positive and Gram negative bacteria
ncluding H. pylori. Additionally, licorice is also beneﬁcial
gainst H. pylori due to its anti-adhesive property.25
Dosage of licorice has varied in few clinical studies, such
s in a study by Sreenivasulu Parum et al. in which a dose
f 120 mg/day was used for H. pylori eradication in patients
ith dyspepsia,21 or a dose of 250 mg  TID in PUD with H. pylori
nfection in a study by Rahnama et al.,26 or a tablet of D-Reglis
80 mg  BID in a study by Momeni et al.27
Rahnama et al. compared the effectiveness of quadruple
reatment including licorice to the same regimen using bis-
uth in substitution of licorice in patients with PUD. The
radication rates were 45% and 75% with licorice and bismuth,
espectively, showing higher effectiveness with the regimen
ncluding licorice.26 Momeni et al. compared the same two
uadruple regimens and showed similar eradication rates and
oncluded that D-Reglis can be a substitute for bismuth in
uadruple regimen.27
In patients with PUD our results showed signiﬁcantly
igher eradication rate of H. pylori in the LR group compared
ith the control group (p = 0.03), in line with the report by Rah-
ama et al. However, the eradication rate with licorice was
ot different from the control group in patients with dys-
epsia (p = 0.18), as found by Momeni et al. The discrepancy
etween the results reported by Rahnama et al. and Momeni
t al. is due to the of patients studied. Rahnama et al. eval-
ated the H. pylori eradication in patients with PUD whereas
he study by Momeni et al. entered patients with both PUD and
UD.
Another debatable issue regarding the effect of licorice on
. pylori eradication is the duration of treatment for improving
atients’ symptoms of dyspepsia. In a clinical study Raveendra
t al. evaluated the effect of licorice against placebo in func-
ional dyspepsia and found that those who received licorice for
ne month had a lower Nepean Dyspepsia Index and thereforeshowed better improvement of symptoms compared to those
who received placebo.28
In a study by Sreenivasulu Puram et al. patients suffering
for dyspepsia with H. pylori infection were prescribed licorice
at a dose of 120 mg  a day for 60 days. The response rate was
compared against the placebo using the HPSA test on days
30 and 60; showing that HPSA test on day 60 was negative
in 56% of licorice group against 4% with placebo denoting a
statistically signiﬁcant difference.21
Based on above two studies it seems that licorice in dyspep-
sia, besides its antimicrobial nature in H. pylori infection, has
also anti-inﬂammatory effect. Therefore, generally speaking
prescribing licorice for H. pylori eradication at a higher dose,
and longer duration should also be considered.
Conclusion
Because of the unsatisfactory rate of H. pylori eradication by the
standard triple regimen, especially in areas with high resis-
tance rates to clarithromycin and amoxicillin, adding licorice
to the triple regimen signiﬁcantly increase H. pylori eradication
in patients with PUD.
Finally, it is recommended to use licorice in addition to the
triple regimen as ﬁrst line treatment in order to decrease drug
adverse effects and its cost, and to increase patient compli-
ance.
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